ICYMI: The latest as America ’s biopharmaceutical companies work to beat COVID-19
America ’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make significantprogress toward identifying solutions to diagnose, treat and prevent infections from the virus. (Source: The Catalyst)
Source: The Catalyst - August 4, 2020 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company International Reference Pricing Coronavirus Source Type: news

New data show commercially insured patients face  increasingly high cost sharing for brand medicines
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines.IQVIA analyzed trends in cost sharing across seven therapy areas and found that anywhere from 44% to 95% of patients ’ total out-of-pocket spending for brand medicines in 2019 was due to deductibles and coinsurance. Compared to patients who only paid copays for brand medicines, patients with deductibles or coinsurance had significantly higher annual out-of-pocket spending across all seven therapeutic areas. In f act, for patients with complex conditions, like cancer and HIV, spendin...
Source: The Catalyst - July 30, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Out-of-Pocket Costs Let's Talk About Cost Source Type: news

Executive order threatens R & D when we need it most to fight COVID-19
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans afford their medicines, he instead declared war on medical innovation. Our nation ’s priority should be beating COVID-19 and getting America back on its feet economically, but these executive orders do the opposite. (Source: The Catalyst)
Source: The Catalyst - July 30, 2020 Category: Pharmaceuticals Tags: Research and Development International Reference Pricing Coronavirus Source Type: news

Medicare ’s 55th anniversary: Celebrating the success of Part D
Today, we are excited to bring you a special edition of our MedicareCatalystseries in honor of Medicare ’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. To celebrate this milestone, let ’s take a closer look at the success of Medicare’s prescription drug benefit, also known as Part D, over the years.   (Source: The Catalyst)
Source: The Catalyst - July 30, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Medicare Source Type: news

Payers subject 80% of new RA and MS patients to utilization management restrictions
A newanalysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine encountered a utilization management restriction. Of those patients, 3 out of 10 were unable to gain approval from their commercial market health plan to start new treatments their doctors prescribed for them within 30 days. (Source: The Catalyst)
Source: The Catalyst - July 22, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Out-of-Pocket Costs Let's Talk About Cost Source Type: news

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
America ’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (Source: The Catalyst)
Source: The Catalyst - July 22, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Coronavirus Source Type: news

PhRMA submits comments to CMS on Medicaid proposed rule
In response to the Centers for Medicare and Medicaid Services ’ (CMS) proposed rule regarding changes to Medicaid,PhRMA provided feedback on how the changes included would have widespread impacts on the biopharmaceutical marketplace and patient care. Specifically, PhRMA noted two significant areas of concern for the Administration to consider. (Source: The Catalyst)
Source: The Catalyst - July 21, 2020 Category: Pharmaceuticals Tags: Patient Assistance Programs Medicaid Value-Based Contracting Source Type: news

New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19 pandemic gripping the world, we are experiencing a challenging situation that we haven ’t seen since the influenza pandemic of 1918-1919, when a third of the world’s population became infected with the virus and about 675,000 Americans died from the disease. (Source: The Catalyst)
Source: The Catalyst - July 21, 2020 Category: Pharmaceuticals Tags: Vaccines Infectious Diseases New Era of Medicine Coronavirus Source Type: news

By the numbers: A look at the sourcing of API used in medicines consumed in the United States
There has been a lot of focus of late on where active pharmaceutical ingredients (APIs) for medicines are manufactured. While some may claim we are reliant on other countries, putting us at risk of potential shortages, the data tell a different story. In reality, the majority of API, measured in dollar value, used in medicines Americans consume are manufactured right here in the United States. (Source: The Catalyst)
Source: The Catalyst - July 16, 2020 Category: Pharmaceuticals Tags: Manufacturing Source Type: news

New report explores setbacks that bring future cancer success stories
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Giovanni Caforio, M.D.,Bristol Myers SquibbChairman of the Board and CEO andPhRMA Chairman of the Board. (Source: The Catalyst)
Source: The Catalyst - July 16, 2020 Category: Pharmaceuticals Authors: Giovanni Caforio, M.D. Tags: Research and Development PhRMA Member Company Cancer New Era of Medicine Source Type: news

Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
Anew study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite investing a much larger share of its revenue in research and development (R&D) than those industries. (Source: The Catalyst)
Source: The Catalyst - July 14, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Research and Development Let's Talk About Cost Source Type: news

Three reasons why MedPAC ’s latest Part D proposal would be bad for patients
The recentlyreleased Medicare Payment Advisory Commission ’s (MedPAC) report to Congress recommends restructuring the Medicare Part D benefit and allowing plans greater flexibility to implement formulary and utilization management tools to control costs. Unfortunately, MedPAC’s latest Part D reform proposals would be bad for patients by focusing on red ucing government costs, not addressing beneficiaries’ needs. Below are three reasons why. (Source: The Catalyst)
Source: The Catalyst - July 14, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Source Type: news

PhRMA ’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
Recently, Lori Reilly, Chief Operating Officer at PhRMA, participated in a podcast with the Counsel of State Governments (CSG) to discuss the important work the biopharmaceutical industry is doing to combat COVID-19. (Source: The Catalyst)
Source: The Catalyst - July 13, 2020 Category: Pharmaceuticals Authors: Sarah Sutton Tags: Research and Development Vaccines Coronavirus Source Type: news

R & D Focus: 5 things to know about the biopharmaceutical research ecosystem
America ’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases, including cancer, rare diseases and autoimmune conditions. These advancements are due to the productivity of the United States ’ biomedical research ecosystem, which is sustained by a policy framework that is designed to support and ad...
Source: The Catalyst - July 13, 2020 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Intellectual Property & D Focus Coronavirus Source Type: news

New initiative to bridge the gap on antimicrobial innovation
Today, more than 20 leading biopharmaceutical companies are launching theAMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections. (Source: The Catalyst)
Source: The Catalyst - July 9, 2020 Category: Pharmaceuticals Tags: Coronavirus Antimicrobial Resistance Source Type: news

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
America ’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (Source: The Catalyst)
Source: The Catalyst - July 2, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Source Type: news

Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Jay Brown, Human Rights Campaign Foundation's Senior Vice President of Programs, Research and Training on the importance of recognizing Pride Month and the fight for equality for all. (Source: The Catalyst)
Source: The Catalyst - June 30, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Coronavirus Health Equity Source Type: news

How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective ­
As the world continues to feel the impact of COVID-19, the biopharmaceutical industry isworking around the clock to identify and develop safe and effective vaccines to prevent infection, while also researching and developing new therapies to treat those infected with the virus. Given the pressing need, along with the volume of information that remains unknown about the disease,a wide range of approaches are being tested to greatly improve the odds that one or more vaccine candidates will be successful. (Source: The Catalyst)
Source: The Catalyst - June 29, 2020 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Clinical Trials Coronavirus Source Type: news

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Chris Arendt, Ph.D., a leader of Takeda’s oncology team to discuss how the company is ensuring cancer research and medicines continue to benefit patients in the age of COVID-19.“The new normal” has been used to describe the challenging and dy...
Source: The Catalyst - June 24, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: PhRMA Member Company Cancer Coronavirus Source Type: news

In combating COVID-19, science is how we get back to normal
America ’s biopharmaceutical companies are working around the clock to combat a common enemy: COVID-19. As the fight to research and develop innovative treatments and vaccines advances, I’m pleased to share our new TV ad, highlighting how we are working together tohelp end the global pandemic. Beginning today, the ad will appear on national cable and broadcast channels as well as online. (Source: The Catalyst)
Source: The Catalyst - June 24, 2020 Category: Pharmaceuticals Authors: Lori Reilly Tags: Research and Development PhRMA Member Company Coronavirus Source Type: news

Guest post: A post-pandemic crisis: The mental toll on America
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Reza Moghadam, PharmD, MBA, senior director, Population Health& Remote Customer Engagement with Otsuka Pharmaceuticals on the impact of mental health during COVID-19. (Source: The Catalyst)
Source: The Catalyst - June 16, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Mental Health Coronavirus Source Type: news

Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
As we work to combat the current global pandemic, it is especially critical to maintain the stability of our global manufacturing supply chain. Unfortunately, recent policy proposals that would mandate drastic changes to pharmaceutical manufacturing supply chains underestimate thesignificant time, resources and other feasibility challenges and complexities involved. Proponents of these proposals also ignore thestrength of a geographically diverse global supply chain. (Source: The Catalyst)
Source: The Catalyst - June 11, 2020 Category: Pharmaceuticals Tags: Manufacturing Source Type: news

Guest Post: From lab to jab: Vaccine development to prevent COVID-19
Conversations and healthy debate about issues facingour industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Abby Bownas, manager, Adult Vaccine Access Coalition to discuss the importance of COVID-19 vaccine development.The emergence of a novel coronavirus in December 2019 took much of the world by surprise and its rapid spread forced many of us to drastically change ...
Source: The Catalyst - June 11, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development Vaccines Coronavirus Source Type: news

PhRMA awards $100,000 to fund projects that address health inequalities
As part of PhRMA ’s continuing work to address health inequalities, we are awarding $100,000 total in grants to fund four projects that will help improve health outcomes by addressing inequity in health care. Nearly 50 candidates nationwide submitted proposals for the PhRMACOVID-19 Collaborative Actions to Reach Equity (CAREs) grant program, announced in April as part of our observation of National Minority Health Month. (Source: The Catalyst)
Source: The Catalyst - June 10, 2020 Category: Pharmaceuticals Authors: Lori Reilly Tags: Coronavirus Health Equity Source Type: news

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are especially important as innovators work around the clock making substantial investments at risk to develop solutions to help prevent infection and treat those with COVID-19, a disease caused by the novel strain of coronavirus. In fact, many of the existing medicines and investigational medicines in clinical trials for COVID-19 exist today because of IP and other incentives that drove their initial research and . (Source: The Catalyst)
Source: The Catalyst - June 5, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Coronavirus Source Type: news

America ’s global leadership in biopharmaceutical manufacturing
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America ’s leadership and suggesting our reliance on other countries has put us at risk of potential shortages. In reality, a lot of manufacturing occurs right here in the United States. (Source: The Catalyst)
Source: The Catalyst - June 4, 2020 Category: Pharmaceuticals Tags: Economic Impact Manufacturing Source Type: news

What scientific experts are saying about vaccine safety
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean drinking water in leading to some of the most impactful public health advances in history, including the eradication of smallpox and near global elimination of polio. (Source: The Catalyst)
Source: The Catalyst - June 4, 2020 Category: Pharmaceuticals Tags: Research and Development Vaccines New Era of Medicine & D Focus Coronavirus Source Type: news

ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting  patient access
The two largest pharmacy benefit managers (PBMs), CVS Caremark and Express Scripts, have once againincreased the number of medicines on their standard formulary exclusion lists. Medicines excluded from formularies treat many chronic and complex conditions, including depression, diabetes and multiple sclerosis. As these PBMs control over half of the market combined, these changes have widespread implications for patients across the country. (Source: The Catalyst)
Source: The Catalyst - June 1, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Let's Talk About Cost Source Type: news

Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post Juliet K. Choi, executive vice president and chief of staff of the Asian& Pacific Islander American Health Forum (APIAHF), a national health justice organization which influences policy, mobilizes communities, and strengthens programs and organizations to impro...
Source: The Catalyst - May 29, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Coronavirus Source Type: news

IP Explained: Intellectual property system working to combat COVID-19
Biopharmaceutical companies areworking around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among biopharmaceutical companies, universities and governments and rapid progress on nearly400 potential coronavirus treatments and vaccines with more than 1,020 clinical trials under way. (Source: The Catalyst)
Source: The Catalyst - May 28, 2020 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Patents Intellectual Property IP Explained Coronavirus Source Type: news

Guest Post: What will we learn from COVID-19?
Conversations and healthy debate about issues facing our industry and the health care systemare critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomesguest contributors, including patients, stakeholders, innovators and others, to share theirperspectives and point of view. Today, we are pleased to welcome a guest post from AlexanderHardy, chief executive officer, Genentech, A Member of the Roche Group. (Source: The Catalyst)
Source: The Catalyst - May 27, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development PhRMA Member Company Coronavirus Source Type: news

It ’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
The biopharmaceutical industry is committed to ensuring Americans and people around the world have access to the medicines they need. As a result, companies do everything they can to make sure manufacturing of medicines is uninterrupted so that there is enough supply to meet demand. One strategy for maintaining a stable, operational supply chain is geographic diversity.Fact: Geographic diversity is key to the stability of a manufacturing supply chain for a medicine. (Source: The Catalyst)
Source: The Catalyst - May 21, 2020 Category: Pharmaceuticals Tags: Manufacturing Source Type: news

New rule makes it harder for patients to lower their out-of-pocket costs
In the midst of increased financial insecurity for Americans due to the COVID-19 pandemic, it is shocking the Administration finalized a policy change in the 2021 Notice of Benefit and Payment Parameters allowing insurers and pharmacy benefit managers (PBMs) to make it harder for patients to have manufacturer cost-sharing assistance count towards their out-of-pocket caps for medicines. (Source: The Catalyst)
Source: The Catalyst - May 20, 2020 Category: Pharmaceuticals Tags: Drug Cost Out-of-Pocket Costs Let's Talk About Cost Source Type: news

Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
This week is Clinical Trials Awareness Week — an event to recognize the importance of clinical trials, raise public awareness of clinical research and honor clinical research professionals and importantly, volunteer participants for their roles in helping to develop safe and effective medicines. (Source: The Catalyst)
Source: The Catalyst - May 18, 2020 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Clinical Trials COVID-19 Source Type: news

Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
Did you know that biopharmaceutical manufacturers must begin setting up the manufacturing supply chain for a medicine years before that medicine is even approved for use by patients? That ’s a fact that is frequently overlooked by policymakers who are proposing drastic, mandated changes to pharmaceutical supply chains. Changes made to any supply chain require careful consideration and planning, as well as substantial engagement with FDA to obtain regulatory review and approval.Fact: Building a new biopharmaceutical manufacturing facility can take 5 to 10 years, on average, before it is operational and can cost a...
Source: The Catalyst - May 14, 2020 Category: Pharmaceuticals Tags: Manufacturing Source Type: news

PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19
The COVID-19 pandemic has caused a number of disruptions in our health care system, one of which is the ability for seniors to access their infused or injected Part B medicines normally administered in a physician office or hospital outpatient setting. Many seniors are confined to their home during the pandemic because either their age or their health condition makes it far too dangerous to travel to a doctor ’s office, clinic or hospital. These seniors, suffering from complex diseases like multiple sclerosis, kidney disease, cancer, osteoporosis and immune disorders, among others, that require regular care, are amon...
Source: The Catalyst - May 6, 2020 Category: Pharmaceuticals Tags: Part B Source Type: news

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP protections are especially important while biopharmaceutical companies work around the clock to develop solutions to help prevent infection and treat those with COVID-19, a disease cause by the novel strain of coronavirus. In fact, many of the existing medicines and investigational medicines being tested for COVID-19 exist today because of IP and other incentives that drove their research and development. (Source: The Catalyst)
Source: The Catalyst - May 4, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Coronavirus Source Type: news

The continued imperative to protect U.S. innovation worldwide
TheCOVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to addresspressing global health challenges– both now and in the future. PhRMA members are collaborating with others andworking around the clock to research and develop vaccines and treatments to beat the virus. (Source: The Catalyst)
Source: The Catalyst - April 30, 2020 Category: Pharmaceuticals Authors: Chris Moore Tags: Patents Intellectual Property Trade International Reference Pricing Source Type: news

Guest Post: Preserving clinical research sites during the coronavirus pandemic
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - April 29, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development Clinical Trials Coronavirus Source Type: news

Observing National Minority Health Month in the age of COVID-19
Every April, National Minority Health Month is observed. The month is dedicated to continuing to raise awareness about health disparities affecting racial and ethnic minority groups. Each year, briefings highlighting the latest statistics are held, panels discussing next steps to improve underlying social determinants of health are convened and researchers, public health experts and community activists continue to sound the alarm of the harm that years of neglect to communities of color and structural racism have caused in the health outcomes of these communities. As we observe National Minority Health month this year, the...
Source: The Catalyst - April 24, 2020 Category: Pharmaceuticals Authors: Courtney Christian Tags: Coronavirus Health Equity Source Type: news

New report shows nearly 260 vaccines in development, including dozens for COVID-19
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most devastating conditions. (Source: The Catalyst)
Source: The Catalyst - April 23, 2020 Category: Pharmaceuticals Tags: Medicines in Development Research and Development Vaccines New Era of Medicine Coronavirus Source Type: news

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scriptssaved $4.3 billion on medicines last year. Patients in these plans with innovative contracting arrangements taking cholesterol-lowering medicines saved nearly $800,000 out of pocket.  (Source: The Catalyst)
Source: The Catalyst - April 20, 2020 Category: Pharmaceuticals Authors: Katie Koziara Tags: Access Out-of-Pocket Costs Medicaid The Value Collaborative Let's Talk About Cost Source Type: news

Retail medicine spending to remain stable share of overall health care spending through next decade
National Health Expenditure (NHE) data projections recently released by the Centers for Medicare& Medicaid Services (CMS) indicate retail medicine spending grew 3.2% in 2019 and will continue to grow in line with overall health care spending through the next decade. This follows the release of the historical spending trends in December, which showed retail prescription drug spending grew 2.5% in 2018. (Source: The Catalyst)
Source: The Catalyst - April 16, 2020 Category: Pharmaceuticals Tags: Let's Talk About Cost Source Type: news

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
As biopharmaceutical companies continue tofight COVID-19 through research and development, three companies havecreated programs empowering employees with medical or laboratory expertise to completely or partially pause their current roles and volunteer their medical skills to help their local health care organizations. The companies will support their efforts by maintaining the members ’ base pay and providing full benefits. This is just one example of our membership supporting thoseon the frontlines. I was fortunate to connect with four biopharmaceutical company employees who are answering the call to volunteer thei...
Source: The Catalyst - April 15, 2020 Category: Pharmaceuticals Tags: PhRMA Member Company Coronavirus Source Type: news

Guest post: Securing the health care supply chain during COVID-19
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - April 14, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Coronavirus Source Type: news

To the millions affected by COVID-19
In these unprecedented times, it can be hard to feel optimistic, but there are reasons to stay positive.The Food and Drug Administration has expedited approval of diagnostic tests. Hospitals and health care providers across the country are selflessly treating a growing number of COVID-19 patients. Policymakers continue to examine ways to help those affected from the virus ’s economic fallout. Community and religious leaders are providing much-needed support to families and the vulnerable in new ways. And the biopharmaceutical industry is working around the clock to develop solutions to help diagnose and treat those w...
Source: The Catalyst - April 9, 2020 Category: Pharmaceuticals Authors: Stephen J. Ubl and Giovanni Caforio, M.D. Tags: PhRMA Member Company Coronavirus Source Type: news

New infographic: How we are fighting COVID-19
America ’s biopharmaceutical companies have joined forces to fight COVID-19. Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like influenza, malaria and HIV, researchers are working to develop and deliver diagnostics, treatments and vacci nes to save lives and restore the rhythms of daily life for billions of people. (Source: The Catalyst)
Source: The Catalyst - April 8, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Coronavirus Source Type: news

PhRMA submits comments on CMS ’s Part D specialty tier proposal
Yesterday, PhRMAsubmitted comments on a Centers for Medicare& Medicaid Services (CMS) proposed rule on policy and technical changes to Medicare Part D and Medicare Advantage. (Source: The Catalyst)
Source: The Catalyst - April 7, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Source Type: news

Merck ’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
As America ’s biopharmaceutical companies workaround the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR). AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make the medications used to cure the infections they cause ineffective. According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a r...
Source: The Catalyst - April 6, 2020 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Infectious Diseases Coronavirus Source Type: news

The biopharmaceutical industry ’s unique role in responding to COVID-19
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock to find solutions. America ’s biopharmaceutical companies areworking tirelessly to develop ways to diagnose, prevent and treat those with coronavirus.  (Source: The Catalyst)
Source: The Catalyst - April 3, 2020 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development PhRMA Member Company Clinical Trials Infectious Diseases Coronavirus Source Type: news